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Tuberculosis (TB) rates in the United States have continued to decline, reaching their lowest 
point on record in 2007 (1). Although TB is decreasing overall in the United States, there is a 
disproportional increase in TB in foreign-born individuals. For example, in 2007, the TB rate 
among foreign-born persons in the United States was 9.7 times that of U.S.-born persons (1). In 
cities that are home to many newly arriving immigrants and refugees, rates of TB can be well 
above the national average. Additionally, the prevalence of drug-resistant TB and 
extrapulmonary disease is higher among foreign-born persons, making the diagnosis and 
management of these cases both challenging and essential for effective prevention and control of 
TB among newly arriving refugees (2). The rate of TB disease appears to remain high for many 
years after immigration, making it essential that clinicians identify and treat latent tuberculosis 
infection (LTBI) prior to the development of TB disease. In addition, because of the high rate of 
reactivation, health-care providers who serve immigrants and refugees should maintain a high 
index of suspicion, regardless of the results of medical examinations performed overseas (3).  
This document provides an overview of the overseas medical screening process for refugees 
relocating to the United States, and outlines guidelines for clinicians evaluating refugees for TB 
during the medical examination for new arrivals. This document does not replace existing 
guidelines but is meant to highlight specific needs in refugees and should augment and be used in 
conjunction with existing guidelines from national authorities (ATS/CDC/IDSA) and state TB 
control programs. 
Overview of Overseas Pre-departure Tuberculosis Screening for Refugees  
Prior to departure for the United States, all refugees receive an overseas medical examination. 
This examination is to identify individuals with conditions that, by law, necessitate exclusion 
from, or treatment before departure for, the United States. CDC stipulates the content of this 
examination through Technical Instructions (TIs) issued to panel physicians and organizations 
that perform the medical screening examinations. The TB TIs issued in 1991 were revised in 
2007 (4). The TB TIs are being implemented in priority countries on a rolling basis, as 
determined by factors such as refugee volume and burden of tuberculosis disease. Current 
requirements for specific countries, date of implementation for each country, and a comparison 
of the 1991 and 2007 TIs are listed in table 1, and updates can be found at: 
www.cdc.gov/immigrantrefugeehealth/exams/ti/panel/tuberculosis-panel-technical-
instructions.html. 
Panel physicians provide information on screening and treatment results. This information 
accompanies the refugee and should be available to the evaluating provider in the United States. 
In addition, the information is provided through the Electronic Disease Notification (EDN) 
system to individual State health departments. If the evaluating provider in the United States is 
not receiving this information, the state refugee health program should be contacted for 
guidance. This information should always include screening information, as well as any 
diagnostic procedures and treatment rendered, including such data as: 
 Pre-resettlement medical screening evaluations.  
 Pre-departure screening evaluations (screening performed within 3 weeks of departure, 
which includes a medical examination, chest radiograph, and three sputum smears for 
culture and AFB). These requirements are applied when CDC determines the risk of 
importation of tuberculosis is great enough to warrant these efforts for specific 
populations. As such, they are not applied to all refugees.  
o Pre-departure tuberculosis classifications (Table 1)  
o Testing for TB infection documentation  
 Tuberculin skin test documentation (including name of product, expiration 
date, amount administered, and type of product used, such as 5TU PPD-S 
or 2TU of RT 23)  
OR 
 IGRA test documentation, if used.  
o Chest radiograph findings, when performed for screening  
 Pre-departure treatment information  
o Directly observed therapy (DOT) regimen received, including doses of all 
medications, start and completion dates, and periods of interruption.  
 Chest radiograph findings before, during, and after treatment.  
 Laboratory results  
o Sputum smear AFB microscopy results obtained before, during, and after 
treatment.  
o Cultures for mycobacteria obtained before, during, and after treatment, including 
any that were contaminated.  
o Drug susceptibility test results performed on any positive culture.  
 Clinical course, including such information as clinical improvement or lack of 
improvement during and after treatment.  
 
Domestic Refugee Screening for Tuberculosis  
The primary goal of the domestic refugee medical screening evaluation for TB is to identify 
individuals with latent TB infection (LTBI) or TB disease, to facilitate timely treatment and 
control. Individuals with LTBI or disease, and contacts of known cases of disease should be 
treated according to U.S. standards of care 
(www.cdc.gov/nchstp/tb/pubs/mmwrhtml/Maj_guide/Treatment.htm). Cases of confirmed or 
suspected TB disease must be reported to appropriate authorities (i.e., state or local health 
department) for monitoring and further public health intervention, such as contact investigation. 
Some areas may also require reporting of individuals with latent TB infection. 
Medical History and Physical Examination of Refugees for Tuberculosis During 
the Domestic Medical Screening Evaluation 
Tuberculosis disease should infrequently be encountered during the domestic refugee medical 
screening evaluation but, when identified, it may represent primary pulmonary or 
extrapulmonary disease (Appendix A). Patients with TB disease may be minimally symptomatic, 
particularly those with extrapulmonary disease. In fact, some individuals with tuberculosis 
disease, particularly children, may be asymptomatic. Others may deny symptoms due to cultural 
issues, fears or other concerns. 
Symptoms of pulmonary tuberculosis are often indolent and include malaise, weight loss, night 
sweats, cough, pleuritic chest pain, fever, and hemoptysis. Symptoms of extrapulmonary disease 
generally reflect the organ involved (e.g., abdominal pain with gastrointestinal TB). Although 
extrapulmonary TB can be found in virtually any organ of the body, statistically, 
lymphadenopathy is the most commonly identified extrapulmonary manifestation. Symptoms 
may also be nonspecific, such as failure to thrive in children. 
All predeparture medical records for the refugee should be closely reviewed. A thorough medical 
history must be obtained. In addition to current signs or symptoms of disease (e.g., weight loss, 
night sweats, fever, cough), specific information may be helpful in identifying a person at higher 
risk of tuberculosis disease or latent tuberculosis infection: 
 Previous history of TB  
 Illness suggestive of TB (i.e., cough > 3 weeks, dyspnea, weight loss, fever, night sweats 
or hemoptysis)  
 Prior treatment suggestive of TB treatment  
 Prior diagnostic evaluation suggestive of TB  
 Family or household contact with a person who currently has or had TB disease, 
treatment, or diagnostic evaluation suggestive of TB  
In addition, in children, a history of recurrent pneumonias, failure to thrive, or recurrent or 
persistent fevers should increase the provider's index of suspicion. Providers should keep in mind 
that children experience higher rates of extrapulmonary TB disease, including meningitis, and 
disease of the middle ear and mastoid, lymph nodes, bones, joints, and skin. 
The physical examination should include height, weight, temperature, respiratory rate, blood 
pressure, thorough pulmonary examination, and inspection and palpation of all major palpable 
lymph node beds (see history and physical examination guidance document: 
www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/guidelines-history-physical.html). In 
addition, a careful skin examination is important, as it may reveal cutaneous disease, scars from 
scrofula or bacille Calmette-Guérin (BCG) vaccination, or hints of prior chest surgery that may 
alert the clinician. 
Testing Newly Arrived Refugees for Tuberculosis Infect ion and Disease 
Screening Tests 
Screening can be performed by using one of two modalities: the Mantoux tuberculin skin test 
(TST) or an interferon-gamma release assay (IGRA) for Mycobacterium tuberculosis (Figure 1). 
Currently, the QuantiFERON®-TB Gold In-tube Test (QFT-G) and T-Spot are two approved 
IGRAs in the United States. Either the TST or an IGRA should be performed during the 
domestic refugee medical screening examination, unless overseas testing results are available. 
There is no reason to repeat a TST if a documented previous positive TST result is available. The 
TST should be repeated if no documentation of a result (in mm induration) is available; however, 
if the refugee reports a history of a previous severe reaction to a TST (e.g. blistering, ulceration), 
repeating the TST is contraindicated. 
Skin Testing 
Interpreting the results of the TST depends on the patient's risk factors (Text Box). In otherwise 
healthy refugees from areas of the world where TB is common, > 10-mm induration is 
considered positive. A cutoff of > 5-mm induration is considered positive in persons with HIV 
infection, those with recent close contact with a known case of infectious TB, persons with 
fibrotic changes in chest radiogram consistent with prior TB, persons with organ transplants, and 
other immunosuppressed persons. Many refugees from TB-endemic areas will have been 
vaccinated against TB with BCG vaccine. Although previous BCG may influence the results of 
the TST, especially in infants, a history of vaccination with BCG should not influence 
interpretation of the TST. The clinician must provide a thorough explanation to the patient of the 
reasons for not considering the BCG in the interpretation of the test. A positive result by TST 
demands further evaluation to exclude TB disease (Figure 1). 
TST testing can be performed in all persons, including children and pregnant women. False-
negative results may be more frequent in young children and in persons with a compromised 
immune system. False negatives also may occur more commonly in persons at high-risk for TB 
(a high pre-test probability). A TST should be administered and read by a trained health-care 
provider. For additional information about performing a TST, visit 
www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm. 
IGRA 
The interferon-gamma release assays (IGRAs) utilize M. tuberculosis complex-specific antigens 
to stimulate patient T- lymphocytes. Importantly, IGRAs do not cross react with antigens related 
to the M. tuberculosis BCG. Sensitized cells, in someone previously exposed to M. tuberculosis, 
will produce the cytokine interferon (IFN)-γ. The QFT-Gold test and third-generation QFTgold 
in-tube test (Cellestis, Victoria, Australia) are based on the quantification of IFN-γ produced by 
T-lymphocytes in whole blood stimulated by M. tuberculosis complex-specific antigens (e.g. 
ESAT-6, CFP-10 and TB7.7). The T-Spot TB Test (Oxford Immunotec, Marlborough, MA) 
measures the number of T-lymphocytes producing IFN-γ when stimulated by M. tuberculosis 
complex-specific antigens. IGRAs are being increasingly used by physicians and health 
departments for evaluation of tuberculosis infection. Clinicians should perform and interpret 
these tests as recommended in national guidelines (5). It should be noted that these tests are 
currently not recommended in those < 5 years of age (5). A positive result by an IGRA 
(indicating infection with the TB mycobacterium) demands further evaluation to exclude TB 
disease (Figure 2). A summary of recommended uses, advantages and disadvantages to the 
IGRA assay can be found at www.cdc.gov/tb/publications/factsheets/testing/IGRA.htm. 
Diagnostic Evaluation 
Chest Radiography: A chest radiograph should be performed for all refugees with a positive TST 
or IGRA test, either prior to immigration or on domestic refugee medical screening; a previous 
history of tuberculosis disease, including those with a Class A or B TB designation from an 
overseas examination; or symptoms consistent with TB disease, regardless of TST or IGRA 
results. A negative TST and/or IGRA does not eliminate TB disease from the differential 
diagnosis of a symptomatic patient. Pregnant women with a positive TST or IGRA should have a 
shielded chest radiograph. If the pregnant woman is asymptomatic and in the first trimester of 
pregnancy, the chest radiograph may be postponed until the second trimester. A posterior-
anterior (PA) radiogram should be performed. In addition to the PA, a lateral radiograph is 
recommended in young children less than 11 years of age, since one of the most common 
findings is hilar adenopathy, which is poorly visualized on a PA film. 
Specimen collection and mycobacterial culture: In the event that a refugee is symptomatic and/or 
has chest radiogram findings or physical findings (such as lymphadenopathy) suggestive of TB 
disease, attempts should be made to collect specimens for acid-fast smear (AFB) and 
mycobacterial culture. If pulmonary disease is suspected, three sputum samples should be 
collected at least 8-24 hours apart, with at least one being an early morning specimen. In 
addition, current CDC guidelines recommend nucleic acid amplification testing be performed on 
at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB 
for whom a diagnosis of TB is being considered but has not yet been established, and for whom 
the test result would alter case management or TB control activities (6). Sputa should be induced 
in persons unable to expectorate spontaneously. Specimens should be collected in either a well-
ventilated area or a sputum collection booth or room with negative pressure. Collection of early 
morning specimens is preferred because of the overnight accumulation of secretions. Sputum 
should be collected under direct observation. This is to ensure that the patient is being properly 
coached and is giving a good coughing effort, as well as to ensure that uncooperative patients are 
producing their own sputum for examination. Children are often unable to expectorate 
voluntarily, so gastric aspirates or hypertonic saline-induced sputum may need to be obtained in 
lieu of a standard sputum sample. Children frequently must be hospitalized to collect adequate 
samples. Since diagnosis and management of children can be very challenging, consultation with 
an experienced and knowledgeable expert in pediatric TB is encouraged. 
In the setting of suspected extrapulmonary disease, consideration should be given to obtaining 
one or more specimens of body fluid or tissue of the suspected site of disease if this can be done 
with an acceptable risk of complications. In general if there are multiple options for obtaining a 
specimen, the least invasive method should be used first (e.g., obtain urine before performing a 
renal biopsy). Because of the increased risk for drug-resistant TB among many refugees, strong 
efforts should be made to obtain adequate specimens for AFB culture, so that drug-susceptibility 
testing may be performed. At least one culture-positive specimen from each patient should have 
conventional drug-susceptibility testing. Rapid drug-susceptibility testing of positive culture 
isolates can be obtained from CDC after consultation with the state health department and may 
be particularly useful in some circumstances (e.g. suspect MDR, or history of previous 
treatment). In addition, some state health department laboratories offer rapid drug-susceptibility 
testing of direct specimens from patients who are at high risk for drug resistance. 
Summary of Diagnostic Classifications  
Diagnosis is based on the results of the clinical evaluation, chest radiograph, screening tests, and 
overseas exam. All refugees will meet one of the following categories. 
Latent TB Infection, No Disease 
Asymptomatic refugee with a positive TST or QFT-G and a negative chest radiograph and 
physical examination. Refugee should be offered treatment for LTBI if not previously treated for 
TB disease or LTBI and no contraindications to LTBI treatment. CDC guidelines for LTBI 
treatment and monitoring should be followed (7). 
TB, Not Clinically Active: 
 Old, healed, not previously treated TB 
 
Asymptomatic refugee with a chest radiograph that indicates old, healed, no TB disease 
(stable chest radiogram) and no history of having received previous TB treatment. 
Refugee should be offered treatment for LTBI as above. 
 Old, healed, previously treated TB  
 
A refugee with no current clinical symptoms who has a chest radiograph that has findings 
consistent with old/healed TB who has a documented history of receiving treatment for 
TB in accordance with current ATS/IDSA/CDC guidelines. No treatment needed.  
Suspect or Confirmed TB Disease 
Screening results indicate suspected or confirmed TB disease. The results may include a 
combination of a positive TST or QFT-G, abnormal chest radiograph or CT scan, pathology 
findings consistent with TB disease (e.g., caseating granuloma), signs and symptoms consistent 
with either pulmonary or extrapulmonary disease, and sputum or tissue smear positive for AFB 
or a culture positive for M. tuberculosis. Immediate follow-up is needed for definitive diagnosis 
and treatment. All suspect or confirmed cases (pulmonary or extrapulmonary) should be reported 
to the local health authorities within 24 hours of determination so that appropriate public health 
measures can be implemented. Cases of suspect TB disease should be reported promptly—do not 
wait for culture confirmation to report suspected TB disease. When pulmonary or laryngeal TB 
is suspected, the patient should be isolated in an appropriate setting to prevent spread of infection 
until the infectious potential is evaluated. 
Overview of Treatment 
All treatment should be administered in accordance with the ATS/CDC/IDSA guidelines for 
treatment of TB: www.cdc.gov/nchstp/tb/pubs/mmwrhtml/Maj_guide/Treatment.htm. 
Latent Tuberculosis Infection (LTBI)  
Standard treatment for latent TB consists of oral isoniazid (INH) for 9 months for all ages. If 
INH is contraindicated alternative regimens are available at 
www.cdc.gov/tb/publications/LTBI/treatment.htm. When utilizing INH, unless the patient has 
underlying medical conditions increasing the risk of liver problems, there is no need to check 
baseline liver function tests (LFT's). However, baseline laboratory testing in patients whose 
initial evaluation suggests a liver disorder is indicated. Baseline hepatic measurements include 
serum aspartate aminotransferase (serum glutamic oxaloacetic transaminase) (AST [SGOT]) or 
alanine aminotransferase (serum glutamic pyruvic transaminase) (AST [SGPT]) and bilirubin. 
Baseline testing is also indicated for patients with HIV infection, pregnant women, and women 
in the immediate postpartum period (i.e., within 3 months of delivery), persons with chronic liver 
disease (e.g. hepatitis B of C, alcoholic hepatitis, or cirrhosis), persons who use alcohol 
regularly, and persons at risk for chronic liver disease. For patients who do need liver testing, 
treatment should be discontinued if a) liver function tests rise to 3 times the upper limit of 
normal if there are signs and symptoms of hepatitis, or b) if LFTs rise to 5 times the upper limit 
of normal if asymptomatic. DOT may be prudent for children less than 5 years of age who are 
close contacts of persons with TB disease. For dosing and monitoring guidelines, please see the 
national LTBI treatment guidelines at www.cdc.gov/mmwr/PDF/rr/rr4906.pdf  [PDF - 350 
KB] and for special considerations see www.cdc.gov/tb/publications/LTBI/treatment.htm. 
Tuberculosis Disease 
National treatment guidelines state that a provider undertaking to treat a patient with TB disease 
is assuming a public health function that includes not only prescribing an appropriate regimen 
but also ensuring adherence to the regimen until treatment is completed. TB disease should be 
treated in consultation with the public health department and a medical expert in the treatment of 
TB. All patients with TB disease should receive therapy under DOT. 
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Table 1. Comparison of 2007 Technical Instructions for Tuberculosis Screening and Treatment 
with 1991 Technical Instructions 





12 months if normal; 6 months if 
Class A condition or Class B1 or 
B2 TB condition 
6 months if no tuberculosis classification or 
only Class B2 TB or Class B3 TB.  3 
months if Class B1 TB, Pulmonary or Class 
B1 TB, Extrapulmonary or for applicants 








Persons >15 years: PA;  
Persons <15 years: PA and lateral 
views in specific circumstances 
PA required for all applicants ≥15 
years.  Applicants <15 years receive CXR if 
they have a TST ≥5 mm (when required 
based on estimated tuberculosis incidence 
rate in country of origin) or have signs and 
Table 1. Comparison of 2007 Technical Instructions for Tuberculosis Screening and Treatment 
with 1991 Technical Instructions 
Category 1991 2007 
symptoms suggestive of tuberculosis, but 
see 42 CFR 34.3 (b)(v). 
TST 
Not routine; used infrequently in 
specific circumstances 
All applicants 2-14 years of age living in 
countries with a WHO-estimated incidence 
rate ≥20 per 100,000.  All applicants who 




Persons >15 years with CXR and/or 
symptoms suggestive of active 
disease (or children <15 years of 
age who are contacts, have history 
of tuberculosis disease, or signs or 
symptoms): AFB smears x 3 
Persons with tuberculosis symptoms, 
abnormal physical examination, or CXR 
suggestive of tuberculosis disease, or who 
are HIV positive: sputum for AFB smear x 
3 plus tuberculosis cultures and DST (for 
persons who cannot produce sputum: 
specimen collection by other means such as 






Consider treatment for other lower 
respiratory infection (no fluoroquinolones) 
if applicable; follow-up CXR for 
immigration medical screening not to be 





Applicants 2-14 years of age or contacts 
who have a TST ≥10 mm but who otherwise 
have a negative evaluation for tuberculosis 
will be classified for U.S. follow-up as 
Class B2 TB, LTBI Evaluation, with TST 




Tuberculosis treatment guidance 
outdated, and minimal guidance for 
drug-resistant tuberculosis 
Treating physicians should follow 
ATS/CDC/IDSA guidelines.  For drug-
resistant patients, treating physicians refer 
also to written guidance from the Francis J. 
Curry National Tuberculosis Center and 
California Department of Health Services, 
2004: Drug-Resistant Tuberculosis: A 
Survival Guide for Clinicians; MDR TB 
expert consultations and CDC consultations 
recommended.   Treatment of drug-resistant 
and MDR TB should be done by or in close 
consultation with experts in the 
Table 1. Comparison of 2007 Technical Instructions for Tuberculosis Screening and Treatment 
with 1991 Technical Instructions 
Category 1991 2007 
management of such cases and in 
coordination with the Division of Global 
Migration and Quarantine (DGMQ). 
Sources of 
tuberculosis drugs 
Source not specified 
Quality-assured drugs: WHO Global Drug 
Facility for first-line drugs and International 
Dispensary Association and WHO Green 





No monitoring after AFB smear 
becomes negative 
Drug susceptible, drug resistant (but not 
MDR) TB: two sputum specimens should 
be collected and submitted for AFB 
microscopy and mycobacteria culture each 
month of therapy until cultures are negative 
for 2 consecutive months. 
MDR TB: two sputum specimens should be 
collected and submitted for AFB 
microscopy and mycobacteria culture each 
month of therapy. 
No drug-susceptibility testing results 
(culture negative):  one sputum specimen 
should be collected and submitted for AFB 
microscopy and mycobacteria culture each 






All applicants to have two sputum 
specimens collected and submitted for AFB 
microscopy and mycobacteria culture at the 






All contacts should have a TST.  If the TST 
is ≥5 mm (or  >10 mm in foreign-born 
persons from high-prevalence countries), 
the contact should be further evaluated with 
medical history, physical examination, and 
CXR.  If the contact is not started on LTBI 
therapy, he or she should receive an 
evaluation with medical history, physical 
examination, and CXR every 3 months until 
departure.   
Table 1. Comparison of 2007 Technical Instructions for Tuberculosis Screening and Treatment 
with 1991 Technical Instructions 
Category 1991 2007 
If the TST is <5 mm and the contact is not 
placed on prophylaxis, the TST should be 
repeated every 3 months until ≥8 weeks 
after contact ends, the index case has 
negative sputum cultures for 2 consecutive 
months, or TST becomes ≥5 mm. 
Children <4 years of age and applicants 
with impaired immunity who are contacts of 
a known tuberculosis case (that is not 
isoniazid resistant) and who have a negative 
evaluation for tuberculosis disease, should 
begin DOPT.  Preventive therapy should be 
discontinued if TST is <5 mm 8 weeks after 
conclusion of exposure to the infectious 
case.    
Contacts cleared for travel should receive a 






Additional screening immediately prior to 
departure (pre-departure evaluation) may be 
required in the event of an outbreak of 
tuberculosis disease or in the setting of 
extremely elevated rates of tuberculosis 
disease.  When required, pre-departure 
screening would occur within 3 weeks of 
departure for all applicants with findings 
suggestive of tuberculosis disease on 
medical history, physical examination, or 
CXR but had negative sputum smears and 
negative cultures.  Pre-departure screening 
would consist of medical history, physical 
exam, CXR, and at least 3 sputum smears 
for AFB microscopy (cultures not required). 
Information 
transfer to CDC 
and state and local 
public health 
Paper: DS medical forms travel 
with refugees and are processed at 
port of entry 
Paper: DS medical forms and additional 
information on tuberculosis treatment travel 
with applicants and are processed at port of 
Table 1. Comparison of 2007 Technical Instructions for Tuberculosis Screening and Treatment 
with 1991 Technical Instructions 
Category 1991 2007 
entry. 
Electronic data transfer of DS medical 
forms, including tuberculosis screening, 
diagnosis and treatment, when available. 
Class A and B1 cases reported to U.S. 
Embassy upon detection. 
No TB 
Classification 
Applicants with normal tuberculosis 
screening examinations 




infectious."  Abnormal CXR and 
one or more positive sputum 
smears. 
Applicants who have tuberculosis disease 
diagnosed (sputum smear positive or culture 
positive) and require treatment overseas but 
who have been granted a waiver to travel 
prior to the completion of therapy. 
Class B1 - 
Pulmonary 
"Tuberculosis clinically active, not 
infectious."  Abnormal CXR and 
sputum smears negative 
No treatment:  Applicants who have 
medical history, physical exam, or CXR 
findings suggestive of pulmonary 
tuberculosis but have negative AFB sputum 
smears and cultures and are not diagnosed 
with tuberculosis or can wait to have 
tuberculosis treatment started after 
immigration. 
Completed treatment:  Applicants who were 
diagnosed with pulmonary tuberculosis and 
successfully completed DOT prior to 
immigration 
Class B1 - 
Extrapulmonary 
"Extrapulmonary tuberculosis, 
clinically active, not 
infectious."  Radiographic or other 
evidence of extrapulmonary 
tuberculosis, clinically active 
Evidence of extrapulmonary tuberculosis 
Class B2 
"Tuberculosis, not clinically 
active."  Abnormal CXR suggestive 
of tuberculosis, not clinically 
active.  No sputum smears required. 
LTBI Evaluation.  Applicants who have a 
tuberculin skin test ≥10 mm but who 
otherwise have a negative evaluation for 
tuberculosis.  
Class B3 "Consistent with tuberculosis, old Contact Evaluation.  Applicants who are a 
Table 1. Comparison of 2007 Technical Instructions for Tuberculosis Screening and Treatment 
with 1991 Technical Instructions 
Category 1991 2007 
or healed."  Abnormal CXR; only 
abnormality is calcified hilar lymph 
node, primary complex, or 
granuloma.  No sputum smears 
required. 
contact of a known tuberculosis case.  
n* AFB, acid-fast bacilli; ATS, American Thoracic Society; CXR, Chest radiograph; DGMQ; 
Division of Global Migration and Quarantine; DOPT, directly observed preventive therapy; DS, 
Department of State; DST, drug-sensitivity testing; HIV, human immunodeficiency virus; IDSA; 
Infectious Diseases Society of America; LTBI, latent tuberculosis infection; MDR TB; 
multidrug-resistant tuberculosis; PA, posterior-anterior; TST, Tuberculin Skin Test; WHO, 
World Health Organization. 
 
TST Testing Interpretation Guidelines for Refugees  
Induration of > 5 mm is considered positive in  
 refugees with HIV  
 refugees known to have been recently in close contact with someone with infectious TB  
 refugees with changes on chest X-ray consistent with prior TB  
 refugees with organ transplants and other immunosuppressed patients  
Induration of > 10 mm is considered positive  
 all other refugees  
Sources of Additional Information: Additional information regarding screening of refugees for 
tuberculosis and other infectious diseases can be obtain by visiting the CDC website at 
www.cdc.gov/ncidod/dq/panel.htm and www.cdc.gov/ncidod/dq/health.htm or at the WHO 
website at www.who.int/tb/surveillanceworkshop/ . 
Appendix A: Summary of Primary Pulmonary and Reactivation Tuberculosis  
Primary pulmonary tuberculosis: Adults with primary pulmonary TB classically present with 
fever, extensive pulmonary infiltrates, and hypoxia. This presentation should be uncommon 
during the domestic refugee medical screening examination, since the overseas medical 
examination should prevent those with TB disease from traveling. However, children and 
immunocompromised hosts may not have these classic symptoms or radiograph findings of TB. 
Therefore, special attention should be paid when evaluating these populations. Children, in 
particular, may have very subtle findings on chest radiogram and may be asymptomatic despite 
having TB disease. They may also present with such symptoms as malaise, failure to thrive or 
weight loss, or a history of recurrent pneumonias. 
Reactivation TB (post-primary tuberculosis): Reactivation of tuberculosis is the clinical scenario 
most likely to be encountered during a refugee screening exam. Reactivation disease often 
manifests years after initial infection and may either be pulmonary or extrapulmonary. 
Progression from TB infection to disease is more likely to occur in older persons or those with 
comorbid conditions, including malnutrition, immunocompromised states (HIV, malignancy, 
diabetes mellitus, immunosuppresent medications), substance abuse and in those who smoke 
tobacco. Other factors common in refugees that may increase the risk of reactivation include 
stress (e.g., stress of immigration) and vitamin D deficiency. 
Glossary of Abbreviations 
 ATS - American Thoracic Society  
 BCG - bacille Calmette-Guérin  
 CDC - Centers for Disease Control and Prevention, United States  
 CXR - Chest radiograph  
 DGMQ - Division of Global Migration and Quarantine  
 DOT - Directly observed therapy  
 DTBE - Division of Tuberculosis Elimination  
 FDA - U.S. Food and Drug Administration  
 EDN - Electronic disease notification  
 HIV - Human immunodeficiency virus  
 IDSA - Infectious Diseases Society of America  
 IGRA - Interferon-gamma release assays  
 LTBI - Latent tuberculosis infection  
 MDR TB - Multidrug-resistant tuberculosis  
 PPD - Purified protein derivative  
 TB - Tuberculosis  
 TI - Technical instructions  
 TU - Tuberculin units  
 TST - Tuberculin skin test  
 QFT - Quantiferon test  
 WHO - World Health Organization  
 
